BACKGROUND & AIMS: Patients with Lynch syndrome have a high risk for colorectal adenomas and carcinomas. We evaluated the development of colorectal neoplasia in these patients. METHODS: We assessed serial colonoscopy findings from 54 persons from 29 pedigrees with pathogenic mutations in MSH2 or MLH1; we evaluated the development of colorectal neoplasia by age, sex, tumor location, and number (mean follow-up time, 9.3 years; colonoscopy interval, 1.7 ± 1.2 years; 112 adenomas and 31 cancers). Differences in colorectal phenotype were analyzed by genotype, and dwell time was calculated for advanced neoplasias. RESULTS: Among mutation carriers, the cumulative risk of colorectal neoplasia was 43% by age 40 years and 72% by 80 years. There were no statistically significant associations between time to development of colorectal neoplasia and sex or mutation type. Most female patients had left-sided neoplasms, whereas most male patients developed right-sided lesions. The mean cumulative numbers of neoplastic lesions in patients were 1.3 ± 0.5 by age 30 years and 7.6 ± 6.8 by age 80 years. Polyp dwell time was 33.0 ± 16.2 months and 35.2 ± 22.3 months for advanced adenoma and colorectal cancer, respectively. The 5-year survival rate for patients with colorectal cancer was 96%. CONCLUSIONS: High percentages of individuals with pathogenic mutations in MSH2 or MLH1 develop colorectal neoplasia by age 40. Left-sided colorectal neoplasias are more frequent in female patients. The development of 3 or more colorectal neoplasms by age 30 years indicates a possible polyposis syndrome rather than Lynch syndrome. Polyp dwell time is short for advanced neoplasias, arguing for annual colonoscopic screening and surveillance.
BACKGROUND & AIMS:Patients with Lynch syndrome have a high risk for colorectal adenomas and carcinomas. We evaluated the development of colorectal neoplasia in these patients. METHODS: We assessed serial colonoscopy findings from 54 persons from 29 pedigrees with pathogenic mutations in MSH2 or MLH1; we evaluated the development of colorectal neoplasia by age, sex, tumor location, and number (mean follow-up time, 9.3 years; colonoscopy interval, 1.7 ± 1.2 years; 112 adenomas and 31 cancers). Differences in colorectal phenotype were analyzed by genotype, and dwell time was calculated for advanced neoplasias. RESULTS: Among mutation carriers, the cumulative risk of colorectal neoplasia was 43% by age 40 years and 72% by 80 years. There were no statistically significant associations between time to development of colorectal neoplasia and sex or mutation type. Most female patients had left-sided neoplasms, whereas most male patients developed right-sided lesions. The mean cumulative numbers of neoplastic lesions in patients were 1.3 ± 0.5 by age 30 years and 7.6 ± 6.8 by age 80 years. Polyp dwell time was 33.0 ± 16.2 months and 35.2 ± 22.3 months for advanced adenoma and colorectal cancer, respectively. The 5-year survival rate for patients with colorectal cancer was 96%. CONCLUSIONS: High percentages of individuals with pathogenic mutations in MSH2 or MLH1 develop colorectal neoplasia by age 40. Left-sided colorectal neoplasias are more frequent in female patients. The development of 3 or more colorectal neoplasms by age 30 years indicates a possible polyposis syndrome rather than Lynch syndrome. Polyp dwell time is short for advanced neoplasias, arguing for annual colonoscopic screening and surveillance.
Authors: K M Lin; M Shashidharan; C A Ternent; A G Thorson; G J Blatchford; M A Christensen; S J Lanspa; S J Lemon; P Watson; H T Lynch Journal: Dis Colon Rectum Date: 1998-04 Impact factor: 4.585
Authors: S J Winawer; R H Fletcher; L Miller; F Godlee; M H Stolar; C D Mulrow; S H Woolf; S N Glick; T G Ganiats; J H Bond; L Rosen; J G Zapka; S J Olsen; F M Giardiello; J E Sisk; R Van Antwerp; C Brown-Davis; D A Marciniak; R J Mayer Journal: Gastroenterology Date: 1997-02 Impact factor: 22.682
Authors: M Aarnio; R Sankila; E Pukkala; R Salovaara; L A Aaltonen; A de la Chapelle; P Peltomäki; J P Mecklin; H J Järvinen Journal: Int J Cancer Date: 1999-04-12 Impact factor: 7.396
Authors: H J Järvinen; M Aarnio; H Mustonen; K Aktan-Collan; L A Aaltonen; P Peltomäki; A De La Chapelle; J P Mecklin Journal: Gastroenterology Date: 2000-05 Impact factor: 22.682
Authors: M G Dunlop; S M Farrington; A D Carothers; A H Wyllie; L Sharp; J Burn; B Liu; K W Kinzler; B Vogelstein Journal: Hum Mol Genet Date: 1997-01 Impact factor: 6.150
Authors: K M Lin; M Shashidharan; A G Thorson; C A Ternent; G J Blatchford; M A Christensen; P Watson; S J Lemon; B Franklin; B Karr; J Lynch; H T Lynch Journal: J Gastrointest Surg Date: 1998 Jan-Feb Impact factor: 3.267
Authors: Sapna Syngal; Randall E Brand; James M Church; Francis M Giardiello; Heather L Hampel; Randall W Burt Journal: Am J Gastroenterol Date: 2015-02-03 Impact factor: 10.864
Authors: Vladimir M Kushnir; Ilke Nalbantoglu; Rao Watson; Jonathan Goodwin; Elyas Safar; Reena V Chokshi; Riad R Azar; Nicholas O Davidson Journal: Dig Dis Sci Date: 2014-06-13 Impact factor: 3.199
Authors: Jinru Shia; Zsofia K Stadler; Martin R Weiser; Efsevia Vakiani; Robin Mendelsohn; Arnold J Markowitz; Moshe Shike; C Richard Boland; David S Klimstra Journal: Fam Cancer Date: 2015-03 Impact factor: 2.375